{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:22:01Z","timestamp":1791386521773,"version":"4.3.3"},"reference-count":21,"publisher":"Oxford University Press (OUP)","issue":"5","license":[{"start":{"date-parts":[[2018,8,31]],"date-time":"2018-08-31T00:00:00Z","timestamp":1535673600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,2,15]]},"DOI":"10.1093\/cid\/ciy554","type":"journal-article","created":{"date-parts":[[2018,7,4]],"date-time":"2018-07-04T23:33:06Z","timestamp":1530747186000},"page":"803-809","source":"Crossref","is-referenced-by-count":72,"title":["Safety and Efficacy of a Novel Vaginal Anti-infective, TOL-463, in the Treatment of Bacterial Vaginosis and Vulvovaginal Candidiasis: A Randomized, Single-blind, Phase 2, Controlled Trial"],"prefix":"10.1093","volume":"68","author":[{"given":"Jeanne M","family":"Marrazzo","sequence":"first","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia C","family":"Dombrowski","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R","family":"Wierzbicki","sequence":"additional","affiliation":[{"name":"Emmes Corporation, Rockville, Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Perlowski","sequence":"additional","affiliation":[{"name":"FHI360, Durham, North Carolina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Pontius","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dwyn","family":"Dithmer","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Washington, Seattle"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Schwebke","sequence":"additional","affiliation":[{"name":"Department of Medicine, University of Alabama at Birmingham"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,8,31]]},"reference":[{"key":"key\n\t\t\t\t2019021500000967300_CIT0001","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1093\/infdis\/jiw121","article-title":"Pathogenesis of bacterial vaginosis: discussion of current hypotheses","volume":"214","author":"Muzny","year":"2016","journal-title":"J Infect Dis"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0002"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0003"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0004","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/OLQ.0b013e3181fbbc95","article-title":"Bacterial vaginosis: identifying research gaps proceedings of a workshop sponsored by DHHS\/NIH\/NIAID","volume":"37","author":"Marrazzo","year":"2010","journal-title":"Sex Trans Dis"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0005","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11908-015-0462-0","article-title":"Vulvovaginal candidiasis in pregnancy","volume":"17","author":"Aguin","year":"2015","journal-title":"Curr Infect Dis Rep"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0006","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/QAI.0b013e3181743936","article-title":"Bacterial vaginosis and vaginal yeast, but not vaginal cleansing, increase HIV-1 acquisition in African women","volume":"48","author":"van de Wijgert","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0007","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1097\/OLQ.0b013e3181b08456","article-title":"Boric acid addition to suppressive antimicrobial therapy for recurrent bacterial vaginosis","volume":"36","author":"Reichman","year":"2009","journal-title":"Sex Transm Dis"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0008","volume-title":"Sexually transmitted disease surveillance, 2015","author":"Centers for Disease Control and Prevention (CDC)","year":"2017"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0009","unstructured":"Citron\n              DM\n            , LeoncioE, TyrrellKL, et al\n          Antimicrobial activity of boric acid (BA) and TOL-463 against vaginal anaerobes causing bacterial vaginosis (BV) and urinary tract infections (UTIs). In: 12th Biennial Congress of the Anaerobe Society of the Americas, Chicago, IL, 28 June\u20131 July 2014."},{"key":"key\n\t\t\t\t2019021500000967300_CIT0010","unstructured":"Citron\n              DM\n            , GoldsteinEJC. Establishment of the MBC\/MFC of boric acid and TOL-463 against culprit vaginitis pathogens and impact on protective vaginal lactobacilli. In: 54th Annual Meeting of Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 5\u20139 September 2014."},{"key":"key\n\t\t\t\t2019021500000967300_CIT0011","doi-asserted-by":"crossref","unstructured":"Fidel\n              PL\n            , LillyEA. Activity of TOL-463 against biofilms formed by Candida species in an ex vivo murine vaginitis model. In: IDWeek, San Diego, CA, 7\u201311 October 2015.","DOI":"10.1093\/ofid\/ofv133.508"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0012","unstructured":"Pulcini\n              E\n            \n          . Effects of boric acid (BA) and TOL-463 against biofilms formed by key vaginitis pathogens Gardnerella vaginalis and Candida albicans. In: 40th Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology, Stowe, VT, 7\u20139 August 2014."},{"key":"key\n\t\t\t\t2019021500000967300_CIT0013","volume-title":"Vulvovaginal candidiasis: development of drugs for treatment, guidance for industry","author":"US Food and Drug Administration, Center for Drug Evaluation and Research (CDER)","year":"2016"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0014","volume-title":"Bacterial vaginosis: development of drugs for treatment, guidance for industry","author":"US Food and Drug Administration, Center for Drug Evaluation and Research (CDER)","year":"2016"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0015"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0016","doi-asserted-by":"crossref","first-page":"678.e1","DOI":"10.1016\/j.ajog.2017.08.017","article-title":"A phase-3, double-blind, placebo-controlled study of the effectiveness and safety of single oral doses of secnidazole 2 g for the treatment of women with bacterial vaginosis","volume":"217","author":"Schwebke","year":"2017","journal-title":"Am J Obstet Gynecol"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0017","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1097\/OLQ.0000000000000300","article-title":"A phase 3, multicenter, randomized, double-blind, vehicle-controlled study evaluating the safety and efficacy of metronidazole vaginal gel 1.3% in the treatment of bacterial vaginosis","volume":"42","author":"Schwebke","year":"2015","journal-title":"Sex Transm Dis"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0018"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0019","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/j.ajog.2005.11.041","article-title":"Suppressive antibacterial therapy with 0.75% metronidazole vaginal gel to prevent recurrent bacterial vaginosis","volume":"194","author":"Sobel","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0020","doi-asserted-by":"crossref","first-page":"e0183765","DOI":"10.1371\/journal.pone.0183765","article-title":"Association between statin use, the vaginal microbiome, and Gardnerella vaginalis vaginolysin-mediated cytotoxicity","volume":"12","author":"Abdelmaksoud","year":"2017","journal-title":"PLoS One"},{"key":"key\n\t\t\t\t2019021500000967300_CIT0021","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1099\/mic.0.081034-0","article-title":"Differences in vaginal microbiome in African American women versus women of European ancestry","volume":"160","author":"Fettweis","year":"2014","journal-title":"Microbiology"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/article-pdf\/68\/5\/803\/27783773\/ciy554.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,2,15]],"date-time":"2019-02-15T00:01:00Z","timestamp":1550188860000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/68\/5\/803\/5088831"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,31]]},"references-count":21,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,8,31]]},"published-print":{"date-parts":[[2019,2,15]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciy554","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,3,1]]},"published":{"date-parts":[[2018,8,31]]}}}